β-Amyloid (25-35) [131602-53-4]
Cat# T14284-1mg
Size : 1mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
β-Amyloid (25-35)
(Synonyms: β-Amyloid peptide(25-35), Aβ25-35, Amyloid beta-peptide(25-35)) Copy Product Info
β-Amyloid (25-35) is a fragment of the Alzheimer’s amyloid beta peptide Aβ(25-35), exhibiting neurotoxic effects and commonly used to establish both cellular and animal models of Alzheimer’s disease.
Cas No. 131602-53-4
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:97.91%
Appearance:Solid
Color:White
COA MS HPLC
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | β-Amyloid (25-35) is a fragment of the Alzheimer’s amyloid beta peptide Aβ(25-35), exhibiting neurotoxic effects and commonly used to establish both cellular and animal models of Alzheimer’s disease. |
| In vitro | The amino acid sequence of β-Amyloid (25-35) is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents the amino acid 25 and the last Met represents the amino acid 35 and it is also investigated in gel state for the first time. Amyloid beta-peptide(25-35) induces apoptotic effects on isolated brain mitochondria and the redox state of methionine-35, plays a key role in the induction of programmed cellular death pathways and toxic events[2]. Comparative studies are also carried out using vibrational absorption and ECD. The conformational preference of Aβ(25-35) peptide film is also investigated using vibrational absorption and VCD spectroscopy[1]. |
| In vivo | The Alzheimer' s disease (AD) model group present with spatial learning and memory impairments. CDS and donepezil administration significantly ameliorate the Aβ25–35 peptide-induced memory impairment in both Morris water maze (P<0.05) and passive avoidance task (P<0.01) compared to the AD model group[3]. Rats are injected with β-Amyloid (25-35) intracerebroventricularly and compound Danshen (CDS) are subsequently administered once daily for 23 days. Rats' behavior is monitored using Morris water maze and passive avoidance. Real time PCR and Western blotting are used in determining amyloid precursor protein (APP), β-site APP cleaved enzyme-1(BACE1), Presenilin-1 (PS1), Insulin-degrading enzyme (IDE) and neprilysin (NEP) in hippocampus. |
| Synonyms | β-Amyloid peptide(25-35), Aβ25-35, Amyloid beta-peptide(25-35) |
| Molecular Weight | 1060.27 |
| Formula | C45H81N13O14S |
| Cas No. | 131602-53-4 |
| Smiles | CCC(C)C(NC(=O)C(NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)CN)C(C)CC)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(O)=O |
| Relative Density. | 1.249g/cm3 |
| Sequence | Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met |
| Sequence Short | GSNKGAIIGLM |
| Storage | Keep away from moisture Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 3.33 mg/mL (3.14 mM), Sonication is recommended. DMSO: 97 mg/mL (91.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (3.11 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||